
The Summary of Product Characteristics (SPC) for Dexdomitor 0.5 mg/ml solution for injection for dogs and cats has been updated.
Section 3.2 (Indications for use for each target species) now includes intravenous administration as a constant rate infusion (CRI) in dogs and cats as part of a multimodal protocol during inhalation anaesthesia.
Section 3.5 (Special precautions for use) highlights that adequate monitoring of respiratory and cardiovascular functions, oxygen supplementation and access to mechanical ventilation should be available during CRI.
The following adverse events can occur when the veterinary medicinal product is administered as a constant rate infusion:
Dogs
Very common (>1 animal/ 10 animals treated) - Arrhythmia (Sinus arrythmia), Bradycardia, Heart block (I and II-degree AV blocks), Vomiting
Common (1 to 10 animals/ 100 animals treated) - Hypotension
Cats
Very common (>1 animal/10 animals treated) - Bradycardia, Heart block (II-degree AV block), High blood pressure, Low blood pressure, Decreased pulse oxygenation, Hypersalivation, Vomiting, Muscle twitching, Agitation, Prolonged recovery, Vocalisation
Any veterinary medicinal product which is authorised for marketing in the United Kingdom has a Summary of Product Characteristics (SPC). The SPC includes information on what adverse events have been known to occur following administration of a particular product, these can be found in either section Adverse events (3.6) or Adverse reactions (4.6). No medicine is 100% risk free.
SPCs are available on our Product Information Database (PID). Once approved by the VMD, the updated SPC that supplies the label text will be available on the PID almost immediately. However, it may take up to 12 months for these changes to appear on marketed packaging.
All updates to SPCs other than template changes, are published in the medicine updates section of VMD Connect.
Reporting of adverse events
We strongly encourage anyone who is aware of an adverse event to report to the Marketing Authorisation Holder (pharmaceutical company, MAH) or the VMD. Provide all relevant information, including the batch number.
Contact details for the MAH can be found on the product leaflet, on the Product Information Database or on the MAH’s website. You can report directly to the VMD at Report a problem with an animal medicine or animal exposed to human medicine - GOV.UK.
You only need to report once, either to the VMD or the MAH. Reporting to both may create duplicate reports which affects the efficiency of our data handling or the quality of the data we hold.
The reporting of adverse events is critical to our ongoing monitoring activities in order to protect animal health, public health, and the environment. Find out more about pharmacovigilance at Monitoring the safety of animal medicines - GOV.UK. Sign up to receive safety updates at Urgent and clinically significant safety updates for veterinary medicines - GOV.UK.